Analysis of Complement C3 Gene Reveals Susceptibility to Severe Preeclampsia
A Inkeri Lokki1,2,3, Tea Kaartokallio2, Ville Holmberg2,4
1Immunobiology, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Insights
Genetic variants in the complement gene C3 are associated with severe preeclampsia (PE). This finding highlights C3
Area of Science:
- Immunogenetics
- Reproductive Medicine
- Human Genetics
Background:
- Preeclampsia (PE) is a common pregnancy complication with a genetic component.
- The complement system's role in PE pathogenesis is suggested but not fully understood.
Purpose of the Study:
- To investigate the association between the central complement gene C3 and severe PE.
- To identify specific genetic variants within C3 linked to PE risk.
Main Methods:
- A genetic case-control study involving Finnish PE patients and controls.
- Genotyping using SNP assays and Sanger sequencing.
- Analysis of single nucleotide polymorphisms (SNPs) and haplotypes within the C3 gene.
Main Results:
- Three SNPs (rs2287845, rs366510, rs2287848) in C3 were significantly associated with severe PE.
- Sixteen SNP haplotypes in C3 showed protective or predisposing effects on severe PE.
- Associated variants are located in functional domains of C3.
Conclusions:
- This study identifies C3 as the first complement gene candidate associated with severe PE.
- Genetic variations in C3 may influence PE pathogenesis.
- Findings may aid in stratifying preeclamptic women for prognosis and treatment.
Abstract:
Preeclampsia (PE) is a common vascular disease of pregnancy with genetic predisposition. Dysregulation of the complement system has been implicated, but molecular mechanisms are incompletely understood. In this study, we determined the potential linkage of severe PE to the most central complement gene, C3. Three cohorts of Finnish patients and controls were recruited for a genetic case-control study. Participants were genotyped using Sequenom genotyping and Sanger sequencing. Initially, we studied 259 Finnish patients with severe PE and 426 controls from the Southern Finland PE and the Finnish population-based PE cohorts. We used a custom-made single nucleotide polymorphism (SNP) genotyping assay consisting of 98 SNPs in 18 genes that encode components of the complement system. Following the primary screening, C3 was selected as the candidate gene and consequently Sanger sequenced. Fourteen SNPs from C3 were also genotyped by a Sequenom panel in 960 patients with severe PE and 705 controls, including already sequenced individuals. Three of the 43 SNPs observed within C3 were associated with severe PE: rs2287845 (p = 0.038, OR = 1.158), rs366510 (p = 0.039, OR = 1.158), and rs2287848 (p = 0.041, OR = 1.155). We also discovered 16 SNP haplotypes with extreme linkage disequilibrium in the middle of the gene with a protective (p = 0.044, OR = 0.628) or a predisposing (p = 0.011, OR = 2.110) effect to severe PE depending on the allele combination. Genetic variants associated with PE are located in key domains of C3 and could thereby influence the function of C3. This is, as far as we are aware, the first candidate gene in the complement system with an association to a clinically relevant PE subphenotype, severe PE. The result highlights a potential role for the complement system in the pathogenesis of PE and may help in defining prognostic and therapeutic subgroups of preeclamptic women.
More Related Videos
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Complement System
